Methods of treating immune diseases by administering antibody polypeptides that antagonize CD40
Antibody polypeptides that specifically bind a novel epitope of human CD40 are provided. The antibody polypeptides do not exhibit CD40 agonist activity. The antibody polypeptides are useful in the treatment of diseases involving CD40 activation, such as autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single V L or V H domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA).
1. A method of treating an immune disease by antagonizing CD40 activity in a patient in need of such treatment, comprising administering to the patient a therapeutically effective amount of antibody polypeptide comprising a first variable domain comprising three complementarity determining regions (CDR), wherein
(a) CDR1 region comprises the amino acid sequence of the CDR1 region of BMS3h-56-269 (amino acids 31 to 35 of SEQ ID NO: 417),
(b) CDR2 region comprises the amino acid sequence of the CDR2 region of BMS3h-56-269 (amino acids 50 to 66 of SEQ ID NO: 417), and
(c) CDR3 region comprises the amino acid sequence of the CDR3 region of BMS3h-56-269 (amino acids 99 to 105 of SEQ ID NO: 417),
or
the amino acid sequences of the CDR1, CDR2, and CDR3 regions are selected from amino acids 31 to 35, 50 to 66, and 99-105, respectively, of one of the antibody polypeptide sequences selected from the group consisting of: SEQ ID NO: 317; SEQ ID NO: 318; SEQ ID NO: 320; SEQ ID NO: 321; SEQ ID NO: 324; SEQ ID NO: 325; SEQ ID NO: 326; SEQ ID NO: 327; SEQ ID NO: 331; SEQ ID NO: 332; SEQ ID NO: 333; SEQ ID NO: 334; SEQ ID NO: 335; SEQ ID NO: 336; SEQ ID NO: 337; SEQ ID NO: 341; SEQ ID NO: 342; SEQ ID NO: 343; SEQ ID NO: 344; SEQ ID NO: 345; SEQ ID NO: 346; SEQ ID NO: 347; SEQ ID NO: 348; SEQ ID NO: 349; SEQ ID NO: 350; SEQ ID NO: 353; SEQ ID NO: 355; SEQ ID NO: 356; SEQ ID NO: 358; SEQ ID NO: 366; SEQ ID NO: 367; SEQ ID NO: 376; SEQ ID NO: 379; SEQ ID NO: 381; SEQ ID NO: 386; SEQ ID NO: 394; SEQ ID NO: 403; SEQ ID NO: 405; SEQ ID NO: 412; and SEQ ID NO: 419,
wherein the antibody polypeptide binds CD40.
2. The method of claim 1 , wherein the first variable domain comprises the amino acid sequence of one of the antibody polypeptides selected from the group consisting of: SEQ ID NO: 317; SEQ ID NO: 318; SEQ ID NO: 320; SEQ ID NO: 321; SEQ ID NO: 324; SEQ ID NO: 325; SEQ ID NO: 326; SEQ ID NO: 327; SEQ ID NO: 331; SEQ ID NO: 332; SEQ ID NO: 333; SEQ ID NO: 334; SEQ ID NO: 335; SEQ ID NO: 336; SEQ ID NO: 337; SEQ ID NO: 341; SEQ ID NO: 342; SEQ ID NO: 343; SEQ ID NO: 344; SEQ ID NO: 345; SEQ ID NO: 346; SEQ ID NO: 347; SEQ ID NO: 348; SEQ ID NO: 349; SEQ ID NO: 350; SEQ ID NO: 353; SEQ ID NO: 355; SEQ ID NO: 356; SEQ ID NO: 358; SEQ ID NO: 366; SEQ ID NO: 367; SEQ ID NO: 376; SEQ ID NO: 379; SEQ ID NO: 381; SEQ ID NO: 386; SEQ ID NO: 394; SEQ ID NO: 403; SEQ ID NO: 405; SEQ ID NO: 412; and SEQ ID NO: 419.
3. The method of claim 1 , wherein the first variable domain comprises the amino acid sequence of BMS3h-56-269 (SEQ ID NO: 417).
4. The method of claim 1 , wherein the amino acid sequence of the first variable domain is set forth in SEQ ID NO: 417.
5. The method of claim 1 , wherein the antibody polypeptide is a domain antibody (dAb).
6. The method of claim 1 , wherein the antibody polypeptide is a fusion polypeptide comprising the first variable domain and an Fc domain.
7. The method of claim 6 , wherein the Fc domain comprises an IgG4 Fc domain.
8. The method of claim 6 , wherein the Fc domain comprises an IgG1 Fc domain.
9. The method of claim 6 , wherein the antibody polypeptide comprises the amino acid sequence of the BMS3h-56-269-IgG1*Fc fusion polypeptide (SEQ ID NO: 1286).
10. The method of claim 6 , wherein the amino acid sequence of the antibody polypeptide is set forth in SEQ ID NO: 1286.
11. The method of claim 6 , wherein the antibody polypeptide comprises the amino acid sequence of the BMS3h-56-269-IgG4 Fc fusion polypeptide (SEQ ID NO: 1287).
12. The method of claim 6 , wherein the amino acid sequence of the antibody polypeptide is set forth in SEQ ID NO: 1287.
13. The method of claim 1 , wherein the antibody polypeptide further comprises a second variable domain that specifically binds a second antigen, wherein the second antigen is an antigen other than human CD40.
14. The method of claim 1 , wherein the antibody polypeptide is administered in combination with an immunosuppressive/immunomodulatory and/or an anti-inflammatory agent.
15. The method of claim 1 , wherein the immune disease is an autoimmune disease or a graft-related disease.
16. The method of claim 1 , wherein the immune disease is selected from the group consisting of: Addison's disease, an allergy, ankylosing spondylitis, asthma, atherosclerosis, an autoimmune disease of the ear, an autoimmune disease of the eye, autoimmune hepatitis, autoimmune parotitis, colitis, coronary heart disease, Crohn's disease, diabetes, Type 1 diabetes, Type 2 diabetes, epididymitis, glomerulonephritis, Graves' disease, Guillain-Barre syndrome, Hashimoto's disease, hemolytic anemia, idiopathic thrombocytopenic purpura, inflammatory bowel disease, an immune response to a recombinant drug product, systemic lupus erythematosus, male infertility, multiple sclerosis, myasthenia gravis, pemphigus, psoriasis, rheumatic fever, rheumatoid arthritis, sarcoidosis, scleroderma, Sjogren's syndrome, a spondyloarthropathy, systemic lupus erythematosus, thyroiditis, a transplant rejection, ulcerative colitis, vasculitis, AIDS, atopic allergy, bronchial asthma, eczema, leprosy, schizophrenia, an inherited depression, an immune disease arising from transplantation of a tissue or an organ, chronic fatigue syndrome, Alzheimer's disease, Parkinson's disease, myocardial infarction, stroke, autism, epilepsy, Arthus's phenomenon, anaphylaxis, alcohol addiction, and drug addiction.
17. The method of claim 16 , wherein the antibody polypeptide comprises the amino acid sequence of the BMS3h-56-269-IgG1*Fc fusion polypeptide (SEQ ID NO: 1286).
18. The method of claim 17 , wherein the immune disease is selected from the group consisting of: ulcerative colitis, Crohn's disease, inflammatory bowel disease, systemic lupus erythematosus, and Sjogren's syndrome.
19. The method of claim 16 , wherein the antibody polypeptide comprises the amino acid sequence of the BMS3h-56-269-IgG4 Fc fusion polypeptide (SEQ ID NO: 1287).
20. The method of claim 19 , wherein the immune disease is selected from the group consisting of: ulcerative colitis, Crohn's disease, inflammatory bowel disease, systemic lupus erythematosus, and Sjogren's syndrome.